BeOne Medicines (6160 HK)

502

Analysis

Health Care • Switzerland

BeOne Medicines is a global oncology biotechnology company focused on the discovery, development, and commercialization of cancer medicines. Its portfolio includes commercial-stage products like BRUKINSA, TEVIMBRA, and PARTRUVIX, which target various blood cancers and solid tumors. The company was founded in 2010 and is headquartered in Basel, Switzerland.

Refresh

Company Presentation • 05 Aug 2026 20:00

Q2 2026

Company Presentation • 25 Aug 2021 21:30

Study update

Company Presentation • 12 Dec 2022 10:00

Study update

Company Presentation • 02 Jun 2026 08:00

Study update

Company Presentation • 06 May 2026 20:00

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Q2 2026

Study update

Study update

Study update

Q1 2026